Physician profile
Thomas John Backenson
NPI 1568562759
$1,216.58
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $479 · 2023: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $737.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $737.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $170.45 | 2022-2023 | Hizentra, Haegarda |
| Glaxosmithkline, LLC. | $138.82 | 2022-2023 | Trelegy Ellipta, Nucala, Arexvy |
| Pfizer INC. | $104.84 | 2022-2023 | |
| Pharming Healthcare, INC. | $90.45 | 2022-2023 | Ruconest |
| Genzyme Corporation | $77.11 | 2022-2023 | |
| Genentech USA, INC. | $68.06 | 2022-2023 | Xolair |
| Biocryst US Sales Co., LLC | $63.25 | 2022-2023 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $61.86 | 2022-2023 | Cuvitru |
| Astrazeneca Pharmaceuticals LP | $61.03 | 2022-2023 | Breztri, Tezspire |
| Novartis Pharmaceuticals Corporation | $54.91 | 2023 | |
| Kaleo, INC. | $52.37 | 2023 | Auvi-Q |
| Regeneron Healthcare Solutions, INC. | $50.45 | 2022-2023 | Dupixent |
| Amgen INC. | $34.39 | 2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.16 | 2022 | |
| Grifols USA, LLC | $27.59 | 2022-2023 | Xembify |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.91 | 2023 | Freestyle Libre 3 |
| Optinose US, INC. | $24.30 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.06 | 2023 | Airduo Digihaler |
| Mylan Specialty L.P. | $17.43 | 2022 | |
| Hikma Pharmaceuticals USA | $16.84 | 2023 | Ryaltris |
| Phadia US INC. | $14.21 | 2023 | Immunocap |
| Octapharma USA, INC. | $14.09 | 2023 | Cutaquig |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Backenson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.